Feedback (LSE:FDBK) Beta: 1.5259 (As of Jun. 25, 2026)


What is Feedback Beta?

Feedback LSE:FDBK -2.74% Beta is 1.5259 as of Jun. 25, 2026. The stock has 4 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Feedback's Beta is 1.5259.


Feedback  (LSE:FDBK) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Feedback Beta Related Terms


Feedback Beta Historical Data

* Premium members only.

The historical data trend for Feedback's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Feedback Beta Chart

Feedback Annual Data
Trend May16 May17 May18 May19 May20 May21 May22 May23 May24 May25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.71 0.48

Feedback Semi-Annual Data
May16 Nov16 May17 Nov17 May18 Nov18 May19 Nov19 May20 Nov20 May21 Nov21 May22 Nov22 May23 Nov23 May24 Nov24 May25 Nov25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.71 0.30 0.48 1.38

LSE:FDBK vs VEEV, BTSG, TEM: Beta Comparison

For the Health Information Services subindustry, Feedback's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Feedback Beta vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Feedback's Beta distribution charts can be found below:

* The bar in red indicates where Feedback's Beta falls into.



Feedback Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 1.5259 mean?
Feedback (LSE:FDBK) has a Beta of 1.5259 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Feedback and its competitors.
Is Feedback's Beta too high?
Feedback's current Beta is 1.5259.
How does Feedback's Beta compare to VEEV and BTSG?
Feedback's Beta of 1.5259 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Healthcare Providers & Services company?
A good Beta depends on the Healthcare Providers & Services industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Feedback and its competitors. Feedback's current Beta is 1.5259. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Feedback stock overvalued right now?
Based on GuruFocus' analysis, Feedback (LSE:FDBK) is currently considered Possible Value Trap. The stock's GF Value™ is £0.14, compared to a current price of £0.07 — trading 49.3% below its estimated fair value. The current Beta is 1.5259. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Feedback (LSE:FDBK), the current Beta is 1.5259 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Feedback Business Description

Other Exchanges GZM0:Germany
Address 3-7 Temple Avenue, 201 Temple Chambers, London, GBR, EC4Y 0DT
Feedback PLC is a medical imaging software and tools company. It develops and markets imaging tools and software for clinical decision-making, and also techniques and improved workflow for medical practitioners engaged in research and in treating patients. Its operating segments include Medical Imaging and Feedback Medical Imaging India. Its products include Bleepa, a regulated communication platform for sharing clinical results and supporting multidisciplinary teamwork, and CareLocker, a patient-facing platform that provides access and control over diagnostic and clinical data.